Viumxidin® (Solution) Instructions for Use
ATC Code
J01XX (Other antibacterial drugs)
Active Substance
Hydroxymethylquinoxalindioxide (Grouping name)
Clinical-Pharmacological Group
Antibacterial drug, a derivative of quinoxaline
Pharmacotherapeutic Group
Systemic antibacterial agents; other antibacterial agents
Pharmacological Action
A broad-spectrum antimicrobial agent, a derivative of quinoxaline. It acts bactericidally.
Active againstProteus vulgaris, Pseudomonas aeruginosa, Friedländer’s bacillus, Escherichia coli, Shigella dysenteria, Shigella flexneri, Shigella boydii, Shigella sonnei, Salmonella spp., Staphylococcus spp., Streptococcus spp., pathogenic anaerobes ( Clostridium perfringens).
It acts on bacterial strains resistant to other antimicrobial drugs, including antibiotics. It does not have a local irritant effect. The development of bacterial drug resistance is possible.
When administered intravenously, it is characterized by a low therapeutic range, which necessitates strict adherence to the recommended doses.
Treatment of burn and purulent-necrotic wounds promotes faster cleansing of the wound surface, stimulates reparative regeneration and marginal epithelialization, and has a beneficial effect on the course of the wound process.
Experimental studies have demonstrated the presence of teratogenic, embryotoxic, and mutagenic effects.
Pharmacokinetics
After intravenous administration, the therapeutic concentration in the blood is maintained for 4-6 hours. The time to reach Cmax in the blood is 1-2 hours after a single administration.
It penetrates well and quickly into all organs and tissues and is excreted by the kidneys. It does not accumulate upon repeated administration.
Indications
For intravenous administration septic conditions (including in patients with burn disease); purulent meningitis; purulent-inflammatory processes with symptoms of generalization.
For intracavitary administration purulent processes in the thoracic and abdominal cavities, including purulent pleurisy; pleural empyema; peritonitis; cystitis; gallbladder empyema; prevention of infectious complications after bladder catheterization.
For external, topical application wound and burn infection (superficial and deep purulent wounds of various locations, long-term non-healing wounds and trophic ulcers, soft tissue phlegmons, infected burns, purulent wounds in osteomyelitis); wounds with the presence of deep purulent cavities (lung abscess, soft tissue abscesses, pelvic tissue phlegmons, postoperative wounds of the urinary and biliary tracts, purulent mastitis); pustular skin diseases.
ICD codes
| ICD-10 code | Indication |
| A40 | Streptococcal sepsis |
| A41 | Other sepsis |
| G00 | Bacterial meningitis, not elsewhere classified |
| J85 | Abscess of lung and mediastinum |
| J86 | Pyothorax (pleural empyema) |
| K65.0 | Acute peritonitis (including abscess) |
| K81.0 | Acute cholecystitis |
| L01 | Impetigo |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L03 | Cellulitis |
| L08.0 | Pyoderma |
| L08.8 | Other specified local infections of skin and subcutaneous tissue |
| L98.4 | Chronic skin ulcer, not elsewhere classified |
| M86 | Osteomyelitis |
| N30 | Cystitis |
| N39.0 | Infection of urinary tract, site not specified |
| N61 | Inflammatory diseases of the breast |
| N73.5 | Unspecified female pelvic peritonitis |
| O91 | Infections of the breast associated with childbirth |
| T30 | Burns and corrosions of unspecified body region |
| T79.3 | Posttraumatic wound infection, not elsewhere classified |
| Z29.2 | Other prophylactic chemotherapy (administration of antibiotics for prophylactic purposes) |
| ICD-11 code | Indication |
| 1B70.1 | Streptococcal cellulitis of the skin |
| 1B70.2 | Staphylococcal cellulitis of the skin |
| 1B70.Z | Bacterial cellulitis or lymphangitis caused by unspecified bacterium |
| 1B72.0 | Bullous impetigo |
| 1B72.1 | Nonbullous impetigo |
| 1B72.Z | Impetigo, unspecified |
| 1B75.0 | Furuncle |
| 1B75.1 | Carbuncle |
| 1B75.2 | Furunculosis |
| 1B75.3 | Pyogenic skin abscess |
| 1B7Y | Other specified pyogenic bacterial infections of skin or subcutaneous tissue |
| 1C44 | Non-pyogenic bacterial infections of skin |
| 1D01.0Z | Bacterial meningitis, unspecified |
| 1G40 | Sepsis without septic shock |
| CA43.Z | Abscess of lung or mediastinum, unspecified |
| CA44 | Pyothorax |
| DC12.0Z | Acute cholecystitis, unspecified |
| DC50.0 | Primary peritonitis |
| DC50.2 | Peritoneal abscess |
| DC50.Z | Peritonitis, unspecified |
| EA40 | Tropical phagedenic ulcer |
| EA50.3 | Staphylococcal scarlet fever |
| EB21 | Pyoderma gangrenosum |
| EF60 | Ischemic ulceration of the skin |
| EM0Z | Unspecified skin disorder |
| FB84.Z | Osteomyelitis or osteitis, unspecified |
| GA05.2 | Unspecified pelvic peritonitis in women |
| GB21.Z | Inflammatory diseases of the breast, unspecified |
| GC00.Z | Cystitis, unspecified |
| GC08.Z | Urinary tract infection, site and agent not specified |
| JB45.Z | Infections of the breast associated with childbirth, unspecified |
| ME60.2 | Ulcerative skin lesion of unspecified nature |
| NE11 | Burn of unspecified body region |
| NF0A.3 | Posttraumatic wound infection, not elsewhere classified |
| QC05.Y | Other specified prophylactic measures |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Solution
Intravenous drip. In severe septic conditions, the maximum single dose is 300 mg, the daily dose is 600 mg.
Intracavitary administration: 10-50 ml of a 1% solution is administered through a drainage tube, catheter, or syringe.
Externally, on the wound surface, previously cleaned of purulent-necrotic masses, apply napkins moistened with a 1% solution daily or every other day, depending on the condition of the burn wound and the course of the wound process. Deep wounds are tamponaded or irrigated with a 0.5% solution. The maximum daily dose is 2.5 g. The duration of treatment is up to 3 weeks.
Adverse Reactions
Possible: allergic reactions.
After intravenous and intracavitary administration – headache, chills, hyperthermia, nausea, vomiting, diarrhea, muscle twitching.
Local reactions periwound dermatitis.
Contraindications
Adrenal insufficiency (including history); pregnancy; lactation period (breastfeeding); children under 18 years of age; hypersensitivity to the active substance.
Use in Pregnancy and Lactation
Contraindicated for use during pregnancy and during lactation (breastfeeding).
Use in Renal Impairment
Use with caution in patients with renal failure.
Pediatric Use
The drug is contraindicated for use in children and adolescents under 18 years of age.
Special Precautions
Use with caution in patients with renal failure.
In chronic renal failure, the dose is reduced. It is prescribed only when other antimicrobial drugs are ineffective.
Storage Conditions
Store at 15°C (59°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Solution for intracavitary and external use 10 mg/ml: 5 ml or 10 ml ampoule 5 or 10 pcs.
Marketing Authorization Holder
Trivium-XXI, LLC (Russia)
Manufactured By
Armavir Biopharmaceutical Plant, FSE (Russia)
Dosage Form
 |
Viumxidin® | Solution for intracavitary and external use 10 mg/ml: 5 ml or 10 ml ampoule 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
Solution for intracavitary and external use light yellow with a greenish tint, transparent.
| 1 ml | |
| Hydroxymethylquinoxalindioxide | 10 mg |
Excipients: water for injections – up to 1 ml.
5 ml – ampoules (10) – cardboard boxes.
10 ml – ampoules (10) – cardboard boxes.
5 ml – ampoules (5) – contour cell packs (1) – cardboard boxes.
5 ml – ampoules (5) – contour cell packs (2) – cardboard boxes.
10 ml – ampoules (5) – contour cell packs (1) – cardboard boxes.
10 ml – ampoules (5) – contour cell packs (2) – cardboard boxes.
Solution for infusion and external use 5 mg/1 ml: amp. 5 ml or 10 ml 5 or 10 pcs.
Marketing Authorization Holder
Trivium-XXI, LLC (Russia)
Manufactured By
Armavir Biopharmaceutical Plant, FSE (Russia)
Dosage Form
|
Viumxidin® | Solution for infusion and external use 5 mg/1 ml: amp. 5 ml or 10 ml 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
Solution for infusion and external use in the form of a transparent light yellow liquid with a greenish tint.
| 1 ml | |
| Hydroxymethylquinoxalindioxide | 5 mg |
Excipients: water for injections – up to 1 ml.
5 ml – glass ampoules (10) – cardboard boxes.
10 ml – glass ampoules (10) – cardboard boxes.
5 ml – glass ampoules (5) – plastic contour trays (1) – cardboard boxes.
5 ml – glass ampoules (5) – plastic contour trays (2) – cardboard boxes.
5 ml – glass ampoules (5) – contour cell packs (1) – cardboard boxes.
5 ml – glass ampoules (5) – contour cell packs (2) – cardboard boxes.
10 ml – glass ampoules (5) – plastic contour trays (1) – cardboard boxes.
10 ml – glass ampoules (5) – plastic contour trays (2) – cardboard boxes.
10 ml – glass ampoules (5) – contour cell packs (1) – cardboard boxes.
10 ml – glass ampoules (5) – contour cell packs (2) – cardboard boxes.
![Viumxidin® [Solution] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Viumxidin® [Solution] 2")